MAZE- Maze Therapeutics, Inc.

Trade Summary

1 week ago, Dandekar Atul, serving as CSBO at Maze Therapeutics, Inc. (MAZE), sold 6,434 shares at $26.24 per share, for a total transaction value of $168,810.96. Following this transaction, Dandekar Atul now holds 32,316 shares of MAZE.

This sale represents a 16.60% decrease in Dandekar Atul's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, September 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, September 4, 2026 at 4:25 PM ET, 2 days after the trade was made.

Maze Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.